{"disease":{"id":"nonvalvular-atrial-fibrillation","name":"Nonvalvular atrial fibrillation","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"xarelto","indication_name":"Nonvalvular atrial fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"rivaroxaban","indication_name":"Nonvalvular atrial fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03374540","title":"Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients","phase":"","overall_status":"COMPLETED","enrollment_count":78517,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02007655","title":"Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation","phase":"","overall_status":"COMPLETED","enrollment_count":6372,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT01885598","title":"Eliquis Regulatory Post Marketing Surveillance","phase":"","overall_status":"COMPLETED","enrollment_count":3335,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04586972","title":"Safety and Efficacy of Apixaban in Very Old Geriatric Subjects (> 80 Years) With Atrial FIbrillation in a Prospective reAl World Study;","phase":"","overall_status":"COMPLETED","enrollment_count":977,"lead_sponsor_name":"Gérond'if","has_results":false},{"nct_id":"NCT07125417","title":"Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"OCEAN-SHD Study Group","has_results":false},{"nct_id":"NCT04942873","title":"The Adherence to Oral Anticoagulant in Chinese Patients With NVAF","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05715658","title":"Pharmacokinetic Study to Evaluate Dabigatran Etexilate in Elderly Subjects","phase":"NA","overall_status":"UNKNOWN","enrollment_count":36,"lead_sponsor_name":"Dongyang Liu","has_results":false},{"nct_id":"NCT05731882","title":"First in Man Study of Left Atrial Appendage Pulsed Field Ablation Occluder","phase":"NA","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Hangzhou Dinova EP Technology Co., Ltd","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}